Search

Displaying results 7471 - 7480 of 9886 in total
  1. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  2. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    It is a broad spectrum of specific HCV proteins.

  3. Drug

    IGN301

    go.drugbank.com/drugs/DB05117
    Experimental

    IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).

  4. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  5. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a

  6. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  8. Drug

    INCB3284

    go.drugbank.com/drugs/DB05130
    Experimental

    INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.

  9. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  10. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...